Ghassan K. Abou-Alfa, Zhenggang Ren, Joseph Patrick Erinjeri, Jeong Heo, Riccardo Lencioni, Yasuaki Arai, Mohamed Bouattour, Maria A. Gonzalez-Carmona, Yabing Guo, Aibing Xu, Gustavo Vasconcelos Alves, Arunee Dechaphunkul, Gwo Fuang Ho, Yueh Ni Lim, Hongtao Hu, Sri Harsha Tekumalla, Vimal Dave, Xavier Monzonis, Masatoshi Kudo, Jia Fan. "Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.17_suppl.lba4000